Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 17

recruiting
3 972
countries
28
conditions
2 103

287 trials match your criteria

Non-small cell lung cancer

Not recruiting

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Non-small cell lung cancer

Not recruiting

Study Comparing Dostarlimab and Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Bladder cancer

Not recruiting

Study on the Effectiveness and Safety of Durvalumab with Gemcitabine and Cisplatin for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Non-small cell lung cancer stage IV

Not recruiting

Study Comparing Nivolumab and Ipilimumab with Chemotherapy to Chemotherapy Alone for Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm

Not recruiting

Study of Futibatinib with Pembrolizumab and Chemotherapy for Patients with Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Non-small cell lung cancer stage III

Not recruiting

Study on Osimertinib and Drug Combination for Adults with Unresectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Transitional cell carcinoma

Not recruiting

Study on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Biliary tract disorder

Not recruiting

Study on Durvalumab and Chemotherapy for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm malignant

Not recruiting

Study on the Safety and Effects of GEN1055 Alone and with Pembrolizumab for Patients with Malignant Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Oropharyngeal squamous cell carcinoma

Not recruiting

Study Comparing Cisplatin and Radiotherapy with Durvalumab and Radiotherapy for Patients with Intermediate Risk HPV-Positive Oropharyngeal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Squamous cell carcinoma of lung+3

Not recruiting

Study Comparing Subcutaneous and Intravenous Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.